Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Fraunhofer-Institute of Toxicology and Experimental Medicine |
---|---|
Information provided by: | Fraunhofer-Institute of Toxicology and Experimental Medicine |
ClinicalTrials.gov Identifier: | NCT00297843 |
Allergic Rhinitis is an inflammatory disease which causes an influx of inflammatory cells and cytokines into the nasal mucosa. These biomarkers can also be found in the nasal secretions. The evaluation of these inflammatory biomarkers is of great interest as this could lead to a concept of measuring the efficacy of anti-allergic treatments by assessing the changes in nasal biomarkers after allergen challenge. To use this model as an assessment of pharmacodynamics it is crucial to evaluate the specificity and reproducibility of cellular and cytokine levels in the nasal secretions after allergen provocations. In a 2 part repeated measurement design 20 patients with allergic rhinitis and 20 healthy subjects will undergo two 4-hour pollen exposures in an interval of 21 days. The aim of this study is to explore the cellular and cytokine levels this allergen challenge will induce in nasal secretions and to assess if an increase in those inflammatory biomarkers is specific to the patient subgroup and whether the results are reproducible after the second allergen challenge.
Condition | Intervention |
---|---|
Seasonal Allergic Rhinitis Healthy Subjects |
Procedure: allergen challenge (grass pollen), nasal lavage |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Convenience Sample, Prospective Study |
Official Title: | A Pilot Monocenter Study to Assess the Reproducibility and Specificity of Cellular and Soluble Biomarkers in Nasal Secretions in Patients With Allergic Rhinitis and Healthy Volunteers Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Fraunhofer ITEM | |
Hannover, Germany, 30625 |
Principal Investigator: | Norbert Krug, MD | Fraunhofer ITEM, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany |
Study ID Numbers: | 06/01 Nabio ITEM |
Study First Received: | February 28, 2006 |
Last Updated: | June 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00297843 History of Changes |
Health Authority: | Germany: Paul-Ehrlich-Institut |
Hypersensitivity Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases Rhinitis, Allergic, Seasonal |
Hypersensitivity, Immediate Rhinitis Healthy Respiratory Hypersensitivity |
Hypersensitivity Otorhinolaryngologic Diseases Respiratory Tract Infections Immune System Diseases Respiratory Tract Diseases |
Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Rhinitis Nose Diseases Respiratory Hypersensitivity |